SCHEDULE 13G: FMR LLC and Abigail P. Johnson Disclose 5.2% Passive Stake in Bicara Therapeutics Inc.
Beneficial Ownership Disclosure
FMR LLC and its affiliates, along with Abigail P. Johnson, have disclosed a passive beneficial ownership of 5.2% of the common stock of Bicara Therapeutics Inc., totaling 2,803,807 shares.
Summary
- FMR LLC and Abigail P. Johnson, through various entities, reported beneficial ownership of 2,803,807 shares of Bicara Therapeutics Inc. common stock.
- This stake represents 5.2% of the total outstanding common stock of Bicara Therapeutics Inc.
- The filing is a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.
- FMR LLC holds sole voting power over 2,803,063 shares and sole dispositive power over 2,803,807 shares.
- Abigail P. Johnson holds sole dispositive power over 2,803,807 shares, reflecting her position as a control person of FMR LLC.
- The filing was made under Rule 13d-1(b), applicable to institutional investors.
- The beneficial ownership is aggregated across various underlying accounts managed by FMR LLC and its subsidiaries, including FIAM LLC, Fidelity Management & Research Company LLC, and IMPRESA MANAGEMENT LLC.
Sentiment
Score: 5
Explanation: Neutral. This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It simply reports a passive investment stake.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Bicara Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are routine for large asset managers like FMR LLC as they cross statutory ownership thresholds, reflecting their investment strategies within the broader market.
Comparison to Industry Standards
- As a Schedule 13G filing, this document primarily serves as a disclosure of beneficial ownership by a large institutional investor. It does not contain performance metrics or operational details of Bicara Therapeutics Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects. The 5.2% stake is a standard threshold for such disclosures.
Stakeholder Impact
- This disclosure primarily impacts shareholders by providing transparency regarding significant institutional ownership. It signals that a major investment firm, FMR LLC, holds a notable passive stake in Bicara Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 01/10/2023 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 01/26/2023 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 01/31/2023 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (accession number -23-000038) for Abigail P. Johnson was incorporated by reference. |
| 02/24/2025 | Date of event which requires filing of this statement (measurement date for ownership). |
| 02/28/2025 | Date of filing of this Schedule 13G. |
Keywords
Bicara Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.